Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$17.63
$23.57
$13.70
▼
$30.99
$1.17B-0.7670,217 shs763,073 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.76
$2.98
$1.96
▼
$6.16
$315.05M1.842.34 million shs2.62 million shs
Immatics N.V. stock logo
IMTX
Immatics
$7.59
$9.04
$7.40
▼
$12.41
$1.04B1.36741,800 shs1.26 million shs
TRAX
First Tracks Biotherapeutics
$33.28
$41.52
$14.72
▼
$49.91
$1.19BN/A707,852 shs1.17 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%-8.22%-23.91%-39.66%+3.46%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+9.52%-11.82%-23.55%-24.18%
Immatics N.V. stock logo
IMTX
Immatics
0.00%-9.32%-20.61%-24.02%-19.26%
TRAX
First Tracks Biotherapeutics
0.00%-3.31%-17.75%+66.07%+3,327,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$17.63
$23.57
$13.70
▼
$30.99
$1.17B-0.7670,217 shs763,073 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$2.76
$2.98
$1.96
▼
$6.16
$315.05M1.842.34 million shs2.62 million shs
Immatics N.V. stock logo
IMTX
Immatics
$7.59
$9.04
$7.40
▼
$12.41
$1.04B1.36741,800 shs1.26 million shs
TRAX
First Tracks Biotherapeutics
$33.28
$41.52
$14.72
▼
$49.91
$1.19BN/A707,852 shs1.17 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
0.00%-8.22%-23.91%-39.66%+3.46%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
0.00%+9.52%-11.82%-23.55%-24.18%
Immatics N.V. stock logo
IMTX
Immatics
0.00%-9.32%-20.61%-24.02%-19.26%
TRAX
First Tracks Biotherapeutics
0.00%-3.31%-17.75%+66.07%+3,327,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
2.75
Moderate Buy$32.6485.12% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.00
Buy$11.50316.67% Upside
Immatics N.V. stock logo
IMTX
Immatics
2.63
Moderate Buy$20.60171.41% Upside
TRAX
First Tracks Biotherapeutics
2.79
Moderate Buy$65.1795.81% Upside

Current Analyst Ratings Breakdown

Latest CATX, TRAX, BCAX, and IMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2026
TRAX
First Tracks Biotherapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/22/2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeEqual Weight
9/18/2026
Immatics N.V. stock logo
IMTX
Immatics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/18/2026
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$7.33 per shareN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$880K358.02N/AN/A$2.79 per share0.99
Immatics N.V. stock logo
IMTX
Immatics
$54.60M19.00N/AN/A$4.09 per share1.86
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$137.95M-$3.10N/AN/AN/AN/A-41.49%-38.59%11/9/2026 (Estimated)
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$103.12MN/AN/AN/AN/A-28,467.97%-41.92%-34.42%11/9/2026 (Estimated)
Immatics N.V. stock logo
IMTX
Immatics
-$222.26M-$1.86N/AN/AN/A-495.71%-47.41%-39.45%11/17/2026 (Estimated)
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A

Latest CATX, TRAX, BCAX, and IMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q2 2026
Immatics N.V. stock logo
IMTX
Immatics
-$0.4748-$0.53-$0.0552-$0.52$12.42 million$10.44 million
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/11/2026Q2 2026
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.8198-$0.82-$0.0002-$0.82N/AN/A
8/10/2026Q2 2026
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$0.2511-$0.22+$0.0311-$0.22$0.09 million$0.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Immatics N.V. stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
11.59
11.59
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
6.61
6.61
Immatics N.V. stock logo
IMTX
Immatics
N/A
7.54
7.54
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Immatics N.V. stock logo
IMTX
Immatics
64.41%
TRAX
First Tracks Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
13.80%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2.99%
Immatics N.V. stock logo
IMTX
Immatics
N/A
TRAX
First Tracks Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
10366.17 million57.04 millionN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
166114.15 million110.74 millionOptionable
Immatics N.V. stock logo
IMTX
Immatics
704136.69 millionN/AOptionable
TRAX
First Tracks Biotherapeutics
10435.73 millionN/AN/A

Recent News About These Companies

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Picked Up by Analysts at Canaccord Genuity Group
October 2 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076707
Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a buy rating
October 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/canaccord-genuity-initiates-coverage-of-first-tracks-biotherapeutics-with-a-buy-rating/ar-AA2dgZvS
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rated "Buy" in New Coverage at Canaccord Genuity Group
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rated-buy-in-new-coverage-at-canaccord-genuity-group-2026-09-30/
30,339 Shares in First Tracks Biotherapeutics $TRAX Bought by Corient Private Wealth LP
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-30339-shares-in-first-tracks-biotherapeutics-trax-bought-by-corient-private-wealth-lp-2026-09-30/
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Average Target Price of $66.55 According to Analysts
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067111
Der aktuelle Kurs der First Tracks Biotherapeutics Inc Aktie beträgt 34,42.
September 26, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Consensus Target Price of $66.55 According to Analysts
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-first-tracks-biotherapeutics-nasdaq-trax-stock-has-consensus-target-price-of-6655-according-to-analysts-2026-09-25/
State Street Corp Buys 1,512,896 Shares of First Tracks Biotherapeutics $TRAX
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-street-corp-buys-1512896-shares-of-first-tracks-biotherapeutics-trax-2026-09-25/
Tidal Investments LLC Makes New Investment in First Tracks Biotherapeutics $TRAX
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-makes-new-investment-in-first-tracks-biotherapeutics-trax-2026-09-22/
Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform
September 18, 2026  |  streetinsider.comhttps://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Outperform/27077856.html
Guggenheim initiates coverage of First Tracks Biotherapeutics with buy
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/guggenheim-initiates-coverage-of-first-tracks-biotherapeutics-with-buy/ar-AA2cnIfO
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rating Upgraded by Guggenheim
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rating-upgraded-by-guggenheim-2026-09-17/
Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Buy%2C/27066556.html
Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Up 5.01%
September 14, 2026  |  aaii.comA
Wellington Management Group LLP Makes New $1.16 Million Investment in First Tracks Biotherapeutics $TRAX
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-makes-new-116-million-investment-in-first-tracks-biotherapeutics-trax-2026-09-12/
Opaleye Management Inc. Invests $1.31 Million in First Tracks Biotherapeutics $TRAX
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-invests-131-million-in-first-tracks-biotherapeutics-trax-2026-09-11/
J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trax-insider-buying-and-selling-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-downgraded-to-sell-rating-by-wall-street-zen-2026-09-05/
First Tracks Biotherapeutics Inc (TRAX)
August 30, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics-financial-summary
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351693/0/en/first-tracks-biotherapeutics-announces-participation-in-september-investor-conferences.html
Analysts Offer Insights on NA Companies: Cerebras Systems, Inc. Class A (CBRS), CitroTech (CITR) and First Tracks Biotherapeutics Inc (TRAX)
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CBRS/pressreleases/3848972/analysts-offer-insights-on-na-companies-cerebras-systems-inc-class-a-cbrs-citrotech-citr-and-first-tracks-biotherapeutics-inc-trax/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$17.63 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$17.62 0.00 (-0.03%)
As of 07:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSEAMERICAN:CATX

$2.76 0.00 (0.00%)
Closing price 10/2/2026 04:10 PM Eastern
Extended Trading
$2.81 +0.05 (+1.78%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Immatics stock logo

Immatics NASDAQ:IMTX

$7.59 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$7.63 +0.04 (+0.53%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

First Tracks Biotherapeutics NASDAQ:TRAX

$33.28 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$33.25 -0.03 (-0.09%)
As of 08:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas